HCB303 / HanchorBio - LARVOL DELTA

HanchorBio Prepares HCB303 Multi-Target Immunotherapy for IND Filing (HanchorBio Press Release) - "HCB303 is a novel fusion protein designed to simultaneously target multiple major immunosuppressive pathways, including PD-L1/PD-1, SIRPα/CD47, and others....In in vitro studies, HCB303 exhibited superior binding and blocking capabilities at its intended targets....In in vivo animal models, HCB303 demonstrated robust tumor inhibition in both human PBMC/tumor co-mixed xenograft model and hTIGIT/hCD47 transgenic mouse model. Treatment with HCB303 led to increased activation of immune cells and a higher proportion of tumor-infiltrating lymphocytes (TILs), supporting its efficacy through multiple immune-modulatory mechanisms....HCB303 is currently in the process development phase, with an IND submission targeted for completion by 2026."

IND • Preclinical • Oncology